Increasing confidence in NAMs for regulatory decision-making

S1: A vision for regulatory application of NAMs – personal reflections (Professor Alan Boobis, Imperial College London)

S2: Overview of recently adopted NAM OECD guidelines and future workplan (Dr Anne Gourmelon, OECD)

S2: Validation and standardisation of latest NAMs (Dr Nicole Kleinstreuer, NICEATM)

S3: Increasing confidence in chemical grouping using omics-derived molecular data (Professor Mark Viant, Michabo Health Science Ltd)

S3: Integrating in vitro bioactivity data, computational modelling and exposure science in animal-free cosmetic safety assessments (Dr Maria Baltazar, Unilever)

S3: Using (Q)SAR models as part of a weight of evidence, to reduce reliance on animal testing and support regulatory assessments (Dr Adrian Fowkes, Lhasa Ltd)

S4: Microphysiological systems – what is possible and what are the limitations? (Dr Jason Ekert, GSK)

S4: Importance of AOPs in NGRA – the case study of cardiotoxicity (Dr Luigi Margiotta-Casaluci, Kings College London)

S4: Novel in vivo mechanistic toxicology approaches to inform regulatory testing (Dr Francisco Inesta-Vaquera, University of Dundee)

S5: Barriers to and opportunities for the increased use of NAMs in the regulation of agrochemicals and biocides (Dr Susy Brescia, HSE CRD)

S5: Non-animal methods and new approach methodologies in UK REACH registration (Dr Helen McGarry, HSE CRD)

S5: The use of NAMs in regulatory assessments of cosmetics safety (Professor Qasim Chaudhry, University of Chester)

S5: Current and future role of NAMs in regulatory assessments of food (Dr David Gott, FSA)

S5: Acceptance of NAMs in the regulation of pharmaceuticals – what are the challenges and how they can be overcome (Dr David Jones, Independent)